Results 121 to 130 of about 1,564,848 (340)

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS

Molecular Systems Biology, 2012
RAS mutations are highly relevant for progression and therapy response of human tumours, but the genetic network that ultimately executes the oncogenic effects is poorly understood.
Iwona Stelniec‐Klotz, Stefan Legewie, Oleg Tchernitsa, Franziska Witzel, Bertram Klinger, Christine Sers, Hanspeter Herzel, Nils Blüthgen, Reinhold Schäfer   +8 more
doaj   +1 more source

Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities. [PDF]

, 2018
The mammary epithelium depends on specific lineages and their stem and progenitor function to accommodate hormone-triggered physiological demands in the adult female.
Abe, Akalin, Alison E. Casey, Ankit Sinha, Asselin-Labat, Buenrostro, Cardiff, Cerami, Cheryl Arrowsmith, Chlebowski, Cox, Cox, Dalia Barsyte-Lovejoy, Daniel De Carvalho, Deugnier, Dos Santos, Edgar, Eirew, Eirew, Eisen, Erik Drysdale, Gary Bader, Gascard, Genevieve Deblois, Gu, Hal Berman, Heinz, Hennighausen, Herschkowitz, Hu, Hui Fang, Huston, Hyeyeon Kim, Ignatchenko, Jackson, Jennifer Cruickshank, Joshi, Joshi, Joshi, Julie Livingstone, Kaltenborn, Kauff, Kelsey, Kendrick, Kiechl, Kislinger, Koboldt, Kotsopoulos, Krueger, Kucera, Labarge, Li, Lim, Lim, Lin, Loenen, Lucas, Lydon, Marotti, Maruyama, Mathieu Lupien, McLean, Meissner, Merico, Michailidou, Michalak, Mohammed, Molyneux, Mona Shehata, Nguyen, Pal, Pathania, Paul C. Boutros, Paul Waterhouse, Pei, Pellacani, Pirashaanthy Tharmapalan, Rajat Singhania, Rama Khokha, Reimand, Rios, Rios, Rugg-Gunn, Ruth Isserlin, Schimanski, Shackleton, Shannon, Shehata, Shiah, Shu, Sigl, Smith, Smyth, Stefan Hofer, Stefan Knapp, Stingl, Storey, Stunnenberg, Subramanian, Swneke Bailey, Thomas Kislinger, Tiago Medina, Tomasetti, van Amerongen, Van Keymeulen, Van Keymeulen, Visvader, Wang, Wojtowicz, Wuidart, Yu-Jia Shiah, Zhang   +111 more
core   +2 more sources

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

AKT isoform-specific expression and activation across cancer lineages

BMC Cancer, 2018
Background Aberrant AKT activation is prevalent across human cancer lineages, providing an important therapeutic target. AKT comprises three isoforms that mediate critical non-redundant, even opposing functions in cancer pathophysiology.
Jue Wang, Wei Zhao, Huifang Guo, Yong Fang, Sarah Elizabeth Stockman, Shanshan Bai, Patrick Kwok-Shing Ng, Yang Li, Qinghua Yu, Yiling Lu, Kang Jin Jeong, Xiaohua Chen, Meng Gao, Jiyong Liang, Wentao Li, Xingsong Tian, Eric Jonasch, Gordon B. Mills, Zhiyong Ding   +18 more
doaj   +1 more source

PSICQUIC and PSISCORE: accessing and scoring molecular interactions [PDF]

, 2012
To the Editor.-- Author Manuscript.-- et al.This study was supported by the European Commission under the Serving Life-science Information for the Next Generation contract 226073; Proteomics Standards Initiative and International Molecular Exchange ...
Aranda, Bruno, De Las Rivas, Javier, Prieto-Sánchez, Carlos   +2 more
core   +2 more sources

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

Recent Developments in Cancer Systems Biology: Lessons Learned and Future Directions. [PDF]

J Pers Med, 2021
Arga KY, Sinha R.
europepmc   +1 more source

The Fire Within: Microbes Inflame Tumors [PDF]

, 2014
The immune system and the microbiota mutually interact to maintain homeostasis in the intestine. However, components of the microbiota can alter this balance and promote chronic inflammation, promoting intestinal tumor development.
Nicola Gagliani, Bo Hu, Samuel Huber, Eran Elinav, Richard A. Flavell, Allen, Anand, Anand, Arthur, Atarashi, Atarashi, Chae, Chen, Couturier-Maillard, Devkota, Elinav, Erdman, Erdman, Fox, Goodwin, Grivennikov, Gueimonde, Hanash, Henao-Mejia, Honda, Hu, Hu, Huber, Huber, Huber, Iida, Ivanov, Ivanov, Jeon, Jiang, Jin, Kinnebrew, Kirchberger, Kostic, Kruis, Kump, Kunde, Langowski, Mazmanian, Medzhitov, Muranski, Normand, Palm, Rakoff-Nahoum, Reddy, Rubinstein, Salcedo, Sobhani, Sonnenberg, van Nood, Vannucci, Viaud, Walker, Wu, Wu, Yoshimoto, Zaki   +61 more
core   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source